EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus

Frédérique Chammartin iD, Amanda Mocroft, Alexander Egle, Robert Zangerle, Colette Smith, Cristina Mussini, Ferdinand Wit, Jörg Janne Vehreschild, Antonella d'Arminio Monforte, Antonella Castagna, Laurent Bailly, Johannes Bogner und 13 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Frédérique Chammartin und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Acquired Immunodeficiency Syndrome, HIV Infections, Neoplasms, Anti-HIV Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Medical Research Council, Austrian HIV Cohort Study.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role of low CD4:CD8 ratio and elevated CD8 cell counts on the risk of cancer remains unclear.

Methods

We investigated the association of CD4:CD8 ratio on the hazard of non-AIDS defining malignancy (NADM), AIDS-defining malignancy (ADM) and most frequent group of cancers in ART-treated people with HIV (PWH) with a CD4 and CD8 cell counts and viral load measurements at baseline. We developed Cox proportional hazard models with adjustment for known confounders of cancer risk and time-dependent cumulative and lagged exposures of CD4:CD8 ratio to account for time-evolving risk factors and avoid reverse causality.

Results

CD4:CD8 ratios below 0.5, compared to above 1.0, were independently associated with a 12-month time-lagged higher risk of ADM and infection-related malignancies (adjusted hazard ratio 2.61 [95% confidence interval {CI }1.10–6.19] and 2.03 [95% CI 1.24–3.33], respectively). CD4 cell counts below 350 cells/μL were associated with an increased risk of NADMs and ADMs, as did infection, smoking, and body mass index-related malignancies.

Conclusions

In ART-treated PWH low CD4:CD8 ratios were associated with ADM and infection-related cancers independently from CD4 and CD8 cell counts and may alert clinicians for cancer screening and prevention of NADM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acquired Immunodeficiency SyndromeHIV InfectionsNeoplasmsAnti-HIV AgentsHumansHIVAnti-Retroviral AgentsCD4 Lymphocyte CountCD4-CD8 RatioViral Load

Stichwörter der Autor:innen

CD4:CD8 ratioHIV infectionantiretroviral therapymalignancyobservational study

Substanzen

Anti-Retroviral AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
  • Austrian HIV Cohort Study (AHIVCOS), Paracelsus Medical University Hospital, Salzburg, Austria.
  • Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, Innsbruck, Austria.
  • The Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom.

ORCID-Profile: Frédérique Chammartin

Förderung

  • NIAID NIH HHS
  • Medical Research Council
  • Austrian HIV Cohort Study
  • Australian HIV Observational Database
  • CHU Saint-Pierre
  • University Hospital Cologne
  • EuroSIDA
  • Frankfurt HIV Cohort Study

Zitieren

APA

Chammartin, F., Mocroft, A., Egle, A., Zangerle, R., Smith, C., Mussini, C., Wit, F., Vehreschild, J. J., d'Arminio Monforte, A., Castagna, A., Bailly, L., Bogner, J., de Wit, S., Matulionyte, R., Law, M., Svedhem, V., Tallada, J., Garges, H. P., Marongiu, A., …, & RESPOND Study Group (2024). Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad671

Vancouver

Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, et al. Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad671

BibTeX
@article{Chammartin2024,
  author = {Chammartin, Frédérique and Mocroft, Amanda and Egle, Alexander and Zangerle, Robert and Smith, Colette and Mussini, Cristina and Wit, Ferdinand and Vehreschild, Jörg Janne and d'Arminio Monforte, Antonella and Castagna, Antonella and Bailly, Laurent and Bogner, Johannes and de Wit, Stéphane and Matulionyte, Raimonda and Law, Matthew and Svedhem, Veronica and Tallada, Joan and Garges, Harmony P and Marongiu, Andrea and Borges, Álvaro H and Jaschinski, Nadine and Neesgaard, Bastian and Ryom, Lene and Bucher, Heiner C and RESPOND Study Group, RESPOND Study Group},
  title = {Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad671}
}
Kostenlos starten →